For example, dual inhibitors of BRD4 and PLK1 that prevent both MYCN transcription and promote N-MYC degradation, respectively, were found to exhibit antitumor effects in preclinical pediatric cancer models [42]. The gene discussed is MYCN; the disease is cancer.